Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GoPro Inc (GPRO) vs Illumina, Inc. (ILMN) Price & Performance

Illumina, Inc.Trade

Price performance (Past 24H)

Key statistics

GoPro Inc vs Illumina, Inc. — how do they compare? GoPro Inc trades at $1.18 (market cap $253.82M), while Illumina, Inc. trades at $265 (market cap $40.43B). The key difference: Illumina, Inc. is far larger — about 159.3× GoPro Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, GoPro Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Illumina, Inc. for 83 Days on average.

GPROILMN
Market Cap
$253.82M$40.43B
Volume
9,909,4662,948,626
Sector
TechnologyHealth
52-Week High
$2.35$293.69
52-Week Low
$0.58$91.00
Typical Hold Time
45 Days83 Days
Enterprise Value
$312.60M$41.79B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GoPro Inc

GoPro (GPRO) trades at $1.18, down 10.61% today amid volatile trading following recent merger announcements. The stock shows bullish technical signals with oversold RSI conditions, while fundamentally the company faces significant challenges with negative profit margins and declining revenue. Recent developments include a proposed $285 million merger with Starman Optical and influencer Markiplier taking an 8.5% stake, driving substantial price volatility.

Investment outlook remains highly speculative with the merger offering potential upside from the $1.14 buyout price, but fundamental weakness and negative cash flow pose substantial risks. Analyst sentiment is mixed with only 21% recommending buy, while ongoing investigations into the merger's fairness add uncertainty to the transaction's completion.

Illumina, Inc.

Illumina (ILMN) trades at $264.40, down 3.34% on the day but up significantly year-to-date with strong technical momentum. The stock shows bullish moving average signals and trades near pivot point resistance at $268. Fundamentally, the company has delivered three consecutive quarterly earnings beats and returned to profitability in 2025 with $850 million net income after previous losses. Recent catalysts include S&P 500 inclusion effective September 21, 2026, and growing AI integration in genomics applications.

The outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI-driven biological data expansion, while risks involve China market headwinds and elevated valuation multiples. Earnings growth and S&P 500 inclusion provide near-term catalysts, but the stock trades at premium valuations with P/E of 49.96 requiring sustained execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

GPRO
92% Buy8% Sell
Avg holding period · 45 Days
ILMN
96% Buy4% Sell
Avg holding period · 83 Days

Top news

Latest headlines on both assets

About GoPro Inc

GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.

Read more on GPRO →

About Illumina, Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Read more on ILMN →